Furthermore, there was evidence that 94% of early-stage high-grade TNBC with a basal-like phenotype expressed MUC1, and MUC1 and EGFR interacted in nucleus of BC cell to facilitate the association of EGFR with transcriptionally active promoter regions, which provided a rationale for MUC1-based immunotherapy in TNBC patients with EGFR expression [53]. Here, MUC1 is linked to breast cancer.